Key result
The development of diastolic dysfunction during 3 months of anthracycline chemotherapy in women with breast cancer was associated with a significantly greater reduction in left ventricular ejection fraction compared to patients who already had diastolic dysfunction at baseline.
Why the study?
Chemotherapy for breast cancer causes serious complications like heart failure; while left ventricular ejection fraction monitors systolic function, diastolic dysfunction may occur earlier.
Observational (n=62)
Yes
Absolute Event Rate: 8.21% vs 0.59%
p-value: p=0.041
Diastolic dysfunction occurs early in breast cancer patients undergoing anthracycline chemotherapy and its development is associated with a significant reduction in left ventricular ejection fraction.
Early diastolic monitoring may flag higher LVEF-risk patients on anthracyclines; hypothesis-generating for prospective trials before practice change.
Background: Chemotherapy for breast cancer is associated with serious cardiovascular complications such as heart failure. The left ventricular ejection fraction is the main parameter used to assess systolic function in these patients. However, the occurrence of diastolic dysfunction may precede that of systolic dysfunction.
No takes yet. Share an insight, caveat, or question.
Barroso et al. (2021) conducted an observational in Breast cancer (n=62). Anthracycline-based chemotherapy vs. Patients with baseline diastolic dysfunction was evaluated on Mean reduction in left ventricular ejection fraction (LVEF) (p=0.041). The development of diastolic dysfunction during 3 months of anthracycline chemotherapy in women with breast cancer was associated with a significantly greater reduction in left ventricular ejection fraction compared to patients who already had diastolic dysfunction at baseline.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: